



OPAL BIOSCIENCES LIMITED

ABN 97 605 631 963

Level 4,

100 Albert Road,

South Melbourne, Victoria, 3205

Australia

Phone: +613 9692 7240

Web: www.opalbiosciences.com

Announcement

Board changes announced

Melbourne, 5 November, 2021: Opal Biosciences Ltd (“Opal”) advises that Mr Hugh Morgan AC will step down as chairman of Opal with effect from today and remain on the board as a non-executive director. Mr Morgan AC has been chairman of Opal since its formation in 2015 as a subsidiary of BioDiem Ltd (“BioDiem”) where he is chairman. BioDiem is Opal’s largest shareholder.

Mr Ken Windle will succeed Mr Morgan as chairman. Mr Windle is currently a non-executive director of the board.

Opal’s strategic focus is now directed towards growing Australia’s vaccine and pharmaceutical manufacturing capability. Australia’s lack of onshore manufacturing capability and risks of reliance on imported medicines has become evident during the current pandemic. Australia’s medical research is world-class however many facilities and expertise are lacking to provide local end-to-end product development.

Mr Hugh Morgan AC said, “With the new opportunities in pharmaceutical manufacturing being explored by Opal I am delighted to hand the company reins to Ken Windle with his deep big pharma experience. Ken has a long history in senior roles with Glaxo/Glaxo Wellcome (now gsk) including on the Group’s Executive Committee, as Head of Global Commercialisation based in London, and as CEO of subsidiaries in UK, Australia, and as Regional President Asia Pacific. More recently Ken has been successful in leading small Australian-based pharmaceutical companies including as CEO of Advent Pharmaceuticals Pty Ltd which he co-founded in 2001 and sold in 2018.

Mr Ken Windle said, “The Board is grateful to Hugh for his stewardship over the past five years and looks forward to his ongoing contributions as a non-executive director to strategy and through his connections. I am excited about Opal’s prospects in manufacturing and looking forward to the challenge of leading the organization as chair. There is a clear need for Australian research to be translated from test tube through to testing and clinical trials and then to patients. Increasing Australia’s ability to manufacture onshore is Opal’s goal.”

- ENDS -

About Opal Biosciences Ltd

Opal Biosciences is an Australian biotechnology company and an innovative player in infectious disease treatment. Opal is currently seeking to diversify its focus by considering commercial opportunities within the Australian biotechnology and pharmaceutical industry. Opal’s strategic focus is now directed towards growing Australia’s vaccine and pharmaceutical manufacturing capability which has become evident as a sovereign need during the recent pandemic

For more information, please visit www.opalbiosciences.com.

Further information

Julie Phillips, Managing Director, Opal Biosciences Ltd

Phone +61 3 9692 7222

Email jphillips@opalbiosciences.com

Twitter @opalbiosciences